Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06106672 | RECRUITING | Myasthenia Gravis

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Sponsor:

COUR Pharmaceutical Development Company, Inc.

Brief Summary:

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Condition or disease

Myasthenia Gravis

Generalized Myasthenia

AChR Myasthenia Gravis

MuSK MG

Intervention/treatment

CNP-106

Placebo

Phase

PHASE1

PHASE2

Detailed Description:

This is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106. The clinical study lasts 222-days (up to 42 days for Screening, 180 Study Days). Subjects ages 18-75 with generalized myasthenia gravis (MG) will be screened up to 42 days prior to enrollment into the clinical study.

Study Type : INTERVENTIONAL
Estimated Enrollment : 54 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
Actual Study Start Date : 2024-05-30
Estimated Primary Completion Date : 2026-06
Estimated Study Completion Date : 2026-08

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
  • 2. Men and non-pregnant women, ages 18-75 years inclusive.
  • 3. Female subjects of childbearing potential must agree not to become pregnant during the clinical study, have a negative pregnancy test at the Screening Visit, and agree to one of the following
    • * Use two highly effective forms of birth control starting at initial screening and continuing throughout the study duration.
    • * Practice abstinence starting at initial screening and continuing throughout the study duration.
    • 4. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class III-IV (Cohort 1). Upon successful DMC review and approval of preliminary safety data obtained from Cohort 1 through Day 15, Cohort 2 will enroll subjects with MGFA Clinical Classification Class II-IV.
    • 5. Subjects positive for anti-AChR antibodies by radioimmunoassay (RIA) (Mayo Clinic).
    • 6, Subjects with MG-ADL Score ≥ 6 at Screening and Baseline Visit with ≥ 50% of the score derived from non-ocular symptoms.
    • 7\. Subjects with QMG Score ≥ 11 at Screening and Baseline Visit. 8. For subjects on any medication used to treat the symptoms of MG (ex. Corticosteroids, pyridostigmine), subjects must be on a stable dose for a minimum of 90 days prior to enrollment and must agree not to increase their dose through clinical study duration unless reviewed and approved by the medical monitor and the site investigator.
    • 9\. Female subjects who agree to not breastfeed starting at initial screening and throughout the study duration.
    • 10\. Female subjects who agree to not donate ova starting at initial screening and throughout the study duration.
    • 11\. Male subjects with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the study duration.
    Exclusion Criteria
    • 1. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class I or V.
    • 2. Subjects with a history of cerebrovascular accident in the past 12 months.
    • 3. Subjects with MG-ADL Score \< 6 at Screen or Subjects with MG-ADL Score ≥ 6 at Screen with ˂ 50% of the score derived from non-ocular symptoms.
    • 4. Subjects with QMG Score \< 11 at Screen.
    • 5. Subjects who have used the following medications
      • * Tacrolimus within 6 months prior to the first dosing;
      • * Methotrexate within 5 half-lives or 90 days after last dose (whichever is longer);
      • * Anti-FcRn inhibitors (ex. Efgartigimod) within 5 half-lives or 90 days after last dose (whichever is longer);
      • * C5 complement inhibitor (ex. Eculizumab) within 5 half-lives or 90 days after last dose (whichever is longer);
      • * Anti-CD20 (ex. Rituximab) within 5 half-lives for 90 days after last dose (whichever is longer);
      • * Inclusion of subjects on other immunomodulatory drugs will be at the discretion of the medical monitor and study site investigator.
      • 6. Subjects who have used immunoglobulins given SC or IV (SCIg or IVIg) or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
      • 7. Subjects who have had thymectomy or any other thymic surgery performed within 12 months prior to Screening.
      • 8. Subjects with untreated thymic malignancy, carcinoma, or thymoma.
      • 9. Subjects with a history of tuberculosis or positive PPD skin test.
      • 10. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to Screening or are planning to receive any vaccination throughout the study duration.
      • 11. Subjects who have received any COVID-19 vaccine within 14 days prior to Screening. Subjects who have received the first dose of any COVID-19 vaccine may not screen for the study until 14 days following their last dose of the vaccine if applicable.
      • 12. Subjects with laboratory test results at Screening or prior to study dosing that are outside the normal limits and considered by the investigator to be clinically significant. Note: Clinically significant laboratory test results at screening that are related to the condition (MG) are acceptable as long as all inclusion and no other exclusion criteria are met.
      • 13. Subjects with positive test results for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at Screening.
      • 14. Subjects with a history of or currently active immune disorders other than MG (including autoimmune disease) unless the condition, after discussion with the medical monitor and study site investigator, has been deemed to be acceptable for the subject's participation in this clinical study.
      • 15. Subjects with a history of or current active diseases other than myasthenia gravis requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the medical monitor and site investigator, has been deemed to be acceptable for the subject's participation in this clinical study.
      • 16. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.
      • 17. Subjects with a complication or medical history of malignancy within the past 5 years which, in the investigator's opinion, makes the subject unsuitable for study participation.
      • 18. Subjects with a history of mast cell activation disease.
      • 19. Subjects who, in the investigator's opinion, will be unable to adhere to study procedures.
      • 20. Subjects who have received an investigational therapy other than CNP-106 within 28 days or 5 half-lives, whichever is longer, prior to Screening.
      • 21. Subjects with any known active condition which, in the investigator's opinion, makes the subject unsuitable for study participation.
      • 22. Known sensitivity to any components of CNP-106 (PLGA, sucrose, mannitol or sodium citrate).
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Location Details

NCT06106672

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

Barrow Neurological Institute

Phoenix, arizona, United States, 85013

NOT YET RECRUITING

United States, Arizona

Neuromuscular Clinic and Research Center

Phoenix, arizona, United States, 85028

RECRUITING

United States, California

Infusion for Health

Brea, California, United States, 92835

RECRUITING

United States, California

University of California, Irvine

Orange, California, United States, 92868

RECRUITING

United States, Connecticut

Yale University

New Haven, Connecticut, United States, 06516

RECRUITING

United States, Florida

Atlantis Research

Miami, florida, United States, 33173

RECRUITING

United States, Florida

Quantix Research, LLC

Miami, florida, United States, 33173

RECRUITING

United States, Florida

University of South Florida

Tampa, florida, United States, 33612

RECRUITING

United States, Illinois

Insight Hospital and Medical Center

Chicago, Illinois, United States, 60608

NOT YET RECRUITING

United States, Kansas

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

RECRUITING

United States, road cancer

Insight Research Institute, Dearborn

Dearborn, road cancer, United States, 48126

RECRUITING

United States, Missouri

University of Missouri, NextGen Precision Health

Columbia, Missouri, United States, 65211

NOT YET RECRUITING

United States, Ohio

Ohio State University Wexner Medical Center

Columbus, Ohio, United States, 43221

NOT YET RECRUITING

United States, South Carolina

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

RECRUITING

United States, Texas

Nerve and Muscle Center of Texas

Houston, Texas, United States, 77030

RECRUITING

United States, Texas

Prolato Clinical Research Center

Houston, Texas, United States, 77054

NOT YET RECRUITING

United States, Virginia

Virginia Commonwealth University

Richmond, Virginia, United States, 23298